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inclusion criteria. Adherence was measured through prospective
cohort studies (N = 3), retrospective analysis of registries (N = 2)
or claims databases (N = 2). Five of the seven studies were based
in Europe and the remainder in the U.S. Adherence measures
reported included medication possession ratios ([MPR], N = 2)
and discontinuation rates based on physician interviews (N = 4)
or patient self-reports (N = 1).Of studies reportingMPRs, 50% to
80% of patients had a MPR  0.80 during the course of therapy.
Studies measuring discontinuation found the percentage of
patients continuing therapy to range from 45% to 79% after one
year of monotherapy. Adherence rates decreased in subsequent
years of treatment. Combination with methotrexate or other
oral RA drugs was associated with higher (N = 2) and lower
(N = 2) adherence rates.CONCLUSIONS: Few studies have mea-
sured adherence to biologics among RA patients; however, most
ﬁnd adherence to such agents is suboptimal. Methods of adher-
ence measurement varied greatly across studies. Standardized
methods to measure and track adherence to biologics are needed
as their use continues to increase.
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OBJECTIVES: Bevacizumab is approved in metastatic non-
small cell lung cancer and is currently tested in adjuvant lung
cancer trials. In this context we explore the potential costs and
health beneﬁts of adding bevacizumab to a cisplatin-based
adjuvant treatment regimen for stage IIa-IIIb patients with
NSCLC and completely resected lung tumors. METHODS: A
four health state Markov Model was used to explore the effects
of adding 1 year adjuvant treatment with bevacizumab to an
existing cisplatin-based treatment regimen. Baseline survival
and relapse risks for cisplatin-treated patients are based on
published data (IALT, International Adjuvant Lung Trial). The
model uses a time-dependent risk of relapse up until six years
after surgery as well as life-long time dependent risk of death.
The effect of bevacizumab is included as a reduction in risk of
relapse based on the expected hazard ratio (HR = 0.79, FDA
approved trial protocol). The effect of bevacizumab is assumed
to be constant for ﬁve years after surgery. Outcomes include
number of relapses, life years, QALYs, direct costs (£), and
incremental cost-effectiveness ratios. A life time horizon is used
as the mean population age at surgery is 60 years. Cost and
outcomes are discounted with 3.5% per annum. Sensitivity
analysis is performed as probabilistic and deterministic sensi-
tivity analysis. RESULTS: The mean undiscounted life expect-
ancy for cisplatin-based chemotherapy treated patients was
estimated to be 10.3 years (7.4 years discounted). The addition
of bevacizumab is estimated to be increased to 11.9 years (8.4
years discounted). The discounted incremental cost-effectiveness
ratio is £39,600/QALY gained. Sensitivity analysis on key vari-
ables show that assumptions on size of risk reduction, duration
of risk reduction as well as baseline risk are the most critical
factors for the ICER. CONCLUSIONS: Adding bevacizumab to
current cisplatin-based treatment regimens for early lung cancer
is predicted to be a cost effective treatment option.
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OBJECTIVES: To evaluate the cost-effectiveness of a combined
primary (vaccination against HPV types 16 and 18) and second-
ary (population-based cervical cancer screening programme)
approach to managing Cervical Intraepithelial Neoplasia (CIN)
1–3 and cervical cancer compared to a cervical cancer screening
programme alone in the Irish health care setting. METHODS:
The economic analysis was conducted using an independently
developed dynamic agent based model [1], which takes account
of the herd immunity effect of the vaccine. The study comparator
was a population based cervical cancer screening programme.
Irish epidemiological and cost data were incorporated into the
model. The analysis was performed from the Irish health
system perspective with a time horizon of 70 years. The cost-
effectiveness of a range of catch-up vaccination strategies were
also evaluated. Costs and beneﬁts were discounted at 3.5%
per annum. A one way and probabilistic sensitivity analysis
were conducted. RESULTS: The base case incremental cost-
effectiveness ratio (ICER) was €17,383/LYG. The ICER for the
12–15 year old catch-up programme was €52,968/LYG. The key
determinants of cost effectiveness were vaccine efﬁcacy, vaccine
costs (including administration costs), duration of protection (i.e.
requirement for booster) and the discount rate. Using a proba-
bilistic sensitivity analysis about the base case, the 95% CI for
cost per LYG was (€9,658, €24,097). CONCLUSIONS: The
results of this HTA suggest that vaccination against HPV types
16 and 18 would be cost-effective from the perspective of the
Irish health care payer. Universal vaccination of 12 year old
females, against HPV types 16 and 18, can be recommended as a
cost-effective intervention in the Irish health care setting. In rela-
tion to a catch-up programme, vaccination of 12 to 15 year old
females in the ﬁrst year of the programme would be the most
cost-effective catch-up strategy. [1] Danish Centre for Health
Technology Assessment (DACEHTA). Reduction in the risk of
cervical cancer by vaccination against HPV—a health technology
assessment. Health Technology Assessment 2007;9.
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OBJECTIVES: Particle therapy (PT) with protons or carbon-ions
is a promising treatment modality for non-small cell lung cancer
(NSCLC). However, its initial investment is high, and it is unclear
whether the potential extra effects are worth the extra costs. The
cost-effectiveness of PT as opposed to stereotactic body radio-
therapy (SBRT) for inoperable stage I NSCLC was examined to
inform the adoption decision for PT. METHODS: A Markov
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